Roctavian approved in US as first gene therapy for hemophilia A - BioWorld Online
| CHGCY Stock | USD 22.00 0.37 1.71% |
Slightly above 53% of Chugai Pharmaceutical's investors are presently thinking to get in. The analysis of overall sentiment of trading Chugai Pharmaceutical Co pink sheet suggests that some investors are interested at this time. Chugai Pharmaceutical's investing sentiment can be driven by a variety of factors including economic data, Chugai Pharmaceutical's earnings reports, geopolitical events, and overall market trends.
Chugai |
Roctavian approved in US as first gene therapy for hemophilia A BioWorld Online
Read at news.google.com
 |
Chugai Pharmaceutical Fundamental Analysis
We analyze Chugai Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chugai Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chugai Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Chugai Pharmaceutical is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Chugai Pharmaceutical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Chugai Pharmaceutical pink sheet to make a market-neutral strategy. Peer analysis of Chugai Pharmaceutical could also be used in its relative valuation, which is a method of valuing Chugai Pharmaceutical by comparing valuation metrics with similar companies.
Peers
Chugai Pharmaceutical Related Equities
| ALPMF | Astellas Pharma | 6.23 | ||||
| SCLX | Scilex Holding | 4.92 | ||||
| PFE | Pfizer | 1.47 | ||||
| BAYZF | Bayer AG | 1.44 | ||||
| RHHBY | Roche Holding | 1.20 | ||||
| NVS | Novartis | 0.86 | ||||
| AZN | AstraZeneca PLC | 0.63 | ||||
| GILD | Gilead Sciences | 0.18 | ||||
| BMYMP | Bristol-Myers Squibb | 0.00 | ||||
| BMY | Bristol Myers | 0.08 | ||||
| JNJ | Johnson Johnson | 0.25 | ||||
| SNY | Sanofi ADR | 0.47 | ||||
| GSK | GlaxoSmithKline PLC | 0.58 | ||||
| MRK | Merck | 1.44 |
Additional Tools for Chugai Pink Sheet Analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.